Income Statement Catalyst Pharmaceuticals, Inc.
Stocks
CPRX
US14888U1016
Pharmaceuticals
|
Market Closed -
Nasdaq
16:00:00 2026-07-14 EDT
|
5-day change | 1st Jan Change | ||
| 31.49 USD | +0.03% |
|
-.--% | +34.92% |
| 08-03 | CDP targets new defense acquisitions after T-Defence deal - sources | RE |
| 08-03 | CDP's new chapter, a push for global companies | AN |
| Fiscal Period: December | 2016 (USD) | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 141M | 214M | 398M | 492M | 589M | |||||
Total Revenues | 141M | 214M | 398M | 492M | 589M | |||||
Cost of Goods Sold, Total | 38.82M | 54.18M | 145M | 81.49M | 99.96M | |||||
Gross Profit | 102M | 160M | 253M | 410M | 489M | |||||
Selling General & Admin Expenses, Total | 49.63M | 58.18M | 134M | 178M | 194M | |||||
R&D Expenses | - | - | - | - | - | |||||
Amortization of Goodwill and Intangible Assets - (IS) | - | - | 32.56M | 37.38M | 37.5M | |||||
Other Operating Expenses, Total | 49.63M | 58.18M | 166M | 215M | 231M | |||||
Operating Income | 52.38M | 102M | 86.81M | 195M | 258M | |||||
Interest And Investment Income | 282K | 3.64M | 4.68M | 16.06M | 24.76M | |||||
Net Interest Expenses | 282K | 3.64M | 4.68M | 16.06M | 24.76M | |||||
Other Non Operating Income (Expenses) | - | - | - | - | - | |||||
EBT, Excl. Unusual Items | 52.67M | 105M | 91.49M | 211M | 283M | |||||
Restructuring Charges | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | -762K | 3.02M | 5.08M | 972K | |||||
Legal Settlements | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 52.67M | 105M | 94.51M | 216M | 284M | |||||
Income Tax Expense | 13.18M | 21.64M | 23.1M | 52.37M | 69.19M | |||||
Earnings From Continuing Operations | 39.48M | 83.08M | 71.41M | 164M | 214M | |||||
Net Income to Company | 39.48M | 83.08M | 71.41M | 164M | 214M | |||||
Net Income - (IS) | 39.48M | 83.08M | 71.41M | 164M | 214M | |||||
Net Income to Common Incl Extra Items | 39.48M | 83.08M | 71.41M | 164M | 214M | |||||
Net Income to Common Excl. Extra Items | 39.48M | 83.08M | 71.41M | 164M | 214M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.38 | 0.8 | 0.67 | 1.38 | 1.75 | |||||
Basic EPS - Continuing Operations | 0.38 | 0.8 | 0.67 | 1.38 | 1.75 | |||||
Basic Weighted Average Shares Outstanding | 103M | 103M | 106M | 118M | 122M | |||||
Net EPS - Diluted | 0.37 | 0.75 | 0.63 | 1.31 | 1.68 | |||||
Diluted EPS - Continuing Operations | 0.37 | 0.75 | 0.63 | 1.31 | 1.68 | |||||
Diluted Weighted Average Shares Outstanding | 108M | 111M | 114M | 125M | 127M | |||||
Normalized Basic EPS | 0.32 | 0.64 | 0.54 | 1.11 | 1.44 | |||||
Normalized Diluted EPS | 0.31 | 0.59 | 0.5 | 1.06 | 1.39 | |||||
Supplemental Items | ||||||||||
EBITDA | 52.58M | 103M | 120M | 233M | 296M | |||||
EBITA | 52.38M | 103M | 119M | 233M | 295M | |||||
EBIT | 52.38M | 102M | 86.81M | 195M | 258M | |||||
EBITDAR | 52.98M | 104M | 120M | 233M | 296M | |||||
Total Revenues (As Reported) | 141M | 214M | 398M | 492M | 589M | |||||
Effective Tax Rate - (Ratio) | 25.03 | 20.66 | 24.44 | 24.22 | 24.4 | |||||
Current Domestic Taxes | - | 16.74M | 40.91M | 61.83M | 75.95M | |||||
Total Current Taxes | 3.87M | 16.74M | 40.91M | 61.83M | 75.95M | |||||
Deferred Domestic Taxes | - | 4.9M | -17.8M | -9.45M | -6.76M | |||||
Total Deferred Taxes | 9.32M | 4.9M | -17.8M | -9.45M | -6.76M | |||||
Normalized Net Income | 32.92M | 65.93M | 57.18M | 132M | 177M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 2.9M | 3.3M | 9.1M | 10M | 13M | |||||
Selling and Marketing Expenses | 2.9M | 3.3M | 9.1M | 10M | 13M | |||||
General and Administrative Expenses | - | - | - | - | - | |||||
Research And Development Expense From Footnotes | 16.94M | 19.79M | 93.15M | 12.65M | 12.71M | |||||
Net Rental Expense, Total | 400K | 431K | 431K | 431K | 431K | |||||
Stock-Based Comp., COGS (Total) | 1.61M | 1.73M | 1.48M | 1.78M | 2.2M | |||||
Stock-Based Comp., R&D Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., SG&A Exp. (Total) | 4.46M | 6.18M | 12.77M | 20.47M | 22.57M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 6.07M | 7.91M | 14.25M | 22.25M | 24.78M |
- Stock Market
- Stocks
- CPRX Stock
- Financials Catalyst Pharmaceuticals, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















